MASH (formerly known as NASH) is a progressive liver disease associated with liver-related complications and death and one of the most febrile areas of pharma R&D as it is widespread – affecting ...

Around 20% or 500 million people with MASLD will go on to develop MASH in their lifetimes, 4 which is already estimated to impact about 115 million adults worldwide. This condition results from ...

U.S. 3 Year Treasury Note 0.0110 3.8990% U.S. 5 Year Treasury Note 0.704 3.994% U.S. 7 Year Treasury Note-0.3140 4.1930% ...

U.S. 3 Year Treasury Note 0.0410 3.8640% U.S. 5 Year Treasury Note 0.742 3.968% U.S. 7 Year Treasury Note-0.297 4.183% ...